03 May 2021 | NewsWebinar video now available - Australia’s COVID-19 vaccine program reset: navigating safety, acceptance and uptakeRead the full article
Serosurveillance provides estimates of antibody levels against infectious diseases and is considered the gold standard for measuring population immunity due to past infection or vaccination. It is an important component of disease surveillance and complements notification, hospitalisation, mortality and immunisation coverage data. National serosurveillance programs are well established in many countries worldwide.
From late April 2020 to early June 2020, NCIRS co-led a seroprevalence survey with Professor John Kaldor and his team from the Kirby Institute at UNSW and NSW Health Pathology’s Institute of Clinical Pathology and Medical Research (ICPMR) to understand population immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19 disease, and to inform clinical and public health responses. The work involved testing blood (serum or plasma) samples from thousands of Australians for SARS-CoV-2 antibodies. Funding for this work was provided to the Australian Partnership for Preparedness Research on Infectious Disease Emergencies (APPRISE) network by the National Health and Medical Research Council (NHMRC) and the Snow Medical Foundation. NCIRS Director Professor Kristine Macartney is an associate investigator in the APPRISE network.
Read the results of the serosurvey here
Read pre-print of the study on MJA website
NCIRS, in collaboration with the Centre for Infectious Diseases and Microbiology Laboratory Services (CIDMLS), at Pathology West – ICPMR, Westmead, commenced a national serosurveillance program in 1996, and has been conducting national serosurveys at approximately 5-yearly intervals. Each serosurvey involves collecting a bank of 7,000–13,000 plasma or serum specimens from diagnostic laboratories throughout Australia that receive samples from hospitalised and ambulant people. The specimens are collected opportunistically from residual/leftover specimens submitted for testing that would otherwise have been discarded and are randomly selected to represent the Australian population.
The collection and storage of specimens is managed by CIDMLS, as is the testing for immunity to the VPDs of interest using disease-specific in-house or commercial serological assays. NCIRS is responsible for the direction of the national program and the subsequent data analysis and interpretation of the serological results. Ethical approval is obtained for each serosurvey.
Serosurvey 1 (1996–1999): measured population immunity to measles, mumps, rubella, varicella, hepatitis A, hepatitis B, hepatitis C, diphtheria, tetanus, polio and pertussis.
Serosurvey 2 (2002): measured population immunity to measles, rubella, varicella, hepatitis B, pertussis, meningococcal C, cytomegalovirus and Helicobacter pylori.
Serosurvey 3 (2007): measured population immunity to measles, mumps, rubella, varicella, pertussis, meningococcal C, diphtheria, tetanus and hepatitis B.
Serosurvey 4 (2012–2013): measured population immunity to measles, mumps, rubella, human papillomavirus and polio.
Serosurvey 5 (2018–2019): collection of specimens is currently underway.
A full list of publications from our serosurveillance program is available here.
We wish to thank the staff of all the laboratories that have contributed sera/plasma to our national serosurvey program for their valuable contribution.
NCIRS, Kids Research, Sydney Children’s Hospitals Network, Cnr Hawkesbury Rd & Hainsworth St, Westmead Locked Bag 4001, Westmead NSW 2145 Tel (612) 9845 1433 | Fax (612) 9845 1418 | ABN 53 188 579 090
We acknowledge that the National Centre for Immunisation Research and Surveillance (NCIRS) is on the land of the traditional owners the Aboriginal and Torres Strait Islander peoples, the First Australians, and recognise their culture, history, diversity and their deep connection to the land. Together, through research and partnership, we aim to move to a place of equity for all. NCIRS also acknowledges and pays respect to other Aboriginal and Torres Strait Islander nations from which our research, staff and community are drawn.
Copyright © 2021 NCIRS. All rights reserved
Our website meets the criteria for credibility and content as defined by the Global Advisory Committee on Vaccine Safety.
Stay updated with the latest from NCIRS